iRhythm Technologies (NASDAQ: IRTC) has recently received a number of price target changes and ratings updates:
- 5/18/2026 – iRhythm Technologies had its price target lowered by Bank of America Corporation from $225.00 to $180.00. They now have a “buy” rating on the stock.
- 5/4/2026 – iRhythm Technologies had its price target raised by Citigroup Inc. from $155.00 to $157.00. They now have a “buy” rating on the stock.
- 5/3/2026 – iRhythm Technologies was upgraded by Wall Street Zen from “hold” to “buy”.
- 5/1/2026 – iRhythm Technologies had its price target lowered by Canaccord Genuity Group Inc. from $198.00 to $180.00. They now have a “buy” rating on the stock.
- 5/1/2026 – iRhythm Technologies had its price target lowered by JPMorgan Chase & Co. from $215.00 to $175.00. They now have an “overweight” rating on the stock.
- 5/1/2026 – iRhythm Technologies had its price target lowered by Wells Fargo & Company from $200.00 to $180.00. They now have an “overweight” rating on the stock.
- 5/1/2026 – iRhythm Technologies had its price target raised by Needham & Company LLC from $254.00 to $255.00. They now have a “buy” rating on the stock.
- 4/25/2026 – iRhythm Technologies was downgraded by Wall Street Zen from “buy” to “hold”.
- 4/21/2026 – iRhythm Technologies had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 4/15/2026 – iRhythm Technologies had its price target lowered by Truist Financial Corporation from $200.00 to $170.00. They now have a “buy” rating on the stock.
- 4/9/2026 – iRhythm Technologies had its price target lowered by The Goldman Sachs Group, Inc. from $184.00 to $147.00. They now have a “neutral” rating on the stock.
Insider Buying and Selling at iRhythm Technologies
In other iRhythm Technologies news, EVP Mervin Smith sold 1,352 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $128.44, for a total transaction of $173,650.88. Following the completion of the sale, the executive vice president owned 25,612 shares of the company’s stock, valued at approximately $3,289,605.28. This represents a 5.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sumi Shrishrimal sold 2,830 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $128.44, for a total transaction of $363,485.20. Following the sale, the executive vice president directly owned 41,870 shares of the company’s stock, valued at $5,377,782.80. This represents a 6.33% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 94,509 shares of company stock worth $12,734,195. Company insiders own 0.98% of the company’s stock.
The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.
See Also
- Five stocks we like better than iRhythm Technologies
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
